financetom
Business
financetom
/
Business
/
Renault's first-half profit beats estimates, sticks to 2024 outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Renault's first-half profit beats estimates, sticks to 2024 outlook
Jul 24, 2024 9:27 AM

LONDON (Reuters) - Renault posted a better-than-expected operating profit for the first half of the year on Wednesday due to strong pricing and new vehicle launches, and stuck to its full-year profit-margin forecast.

The French automaker last week reported that its first-half sales volume rose 1.9% versus the same period in 2023 due to the strong performance of hybrid models in Europe, its key region.

Renault posted a higher operating margin of 8.1% for the first half of the year, up from 7.6% a year earlier and higher than the 7.9% expected by analysts.

This is a key metric for Renault, which has targeted a double-digit operating margin by 2030.

The automaker stuck to its full-year operating margin forecast of 7.4% or above.

Renault returned to growth last year after four consecutive years of declining unit sales, and is hoping that 10 new launches this year will keep the momentum.

The company had hoped to be at the forefront of legacy automakers' efforts to go electric, with a plan for the Renault brand to go fully electric by the end of the decade.

After touting Renault's efforts to electrify, CEO Luca de Meo called this week for a "little more flexibility" in the European Union's planned 2035 ban on combustion engine models.

But demand for EVs has slowed sharply in Europe, with data from the region's trade body showing last week that sales only rose 1.3% in the first half.

Automakers are instead seeing strong demand for more affordable and more convenient hybrids and are rolling out additional models to meet demand.

Renault has launched new hybrid models and executives said last week it will continue to do so.

Renault reported first-half revenue of 26.96 billion euros ($29.26 billion), up 0.4% over the previous year and above market forecasts of 26.9 billion euros.

The company said it currently has a strong order book equivalent to 2.6 months of forward-looking sales.

($1 = 0.9213 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Singapore's top bank DBS eyes $370 billion in wealth assets by 2026, top exec says
Singapore's top bank DBS eyes $370 billion in wealth assets by 2026, top exec says
Jun 12, 2024
By Yantoultra Ngui SINGAPORE (Reuters) - DBS Group plans to boost assets under management for its wealth business to S$500 billion ($369.7 billion) by the end of 2026, said the unit's head, as the top Singaporean bank bets on robust inflows into the city state. Wealth assets at DBS grew 23% to a record S$365 billion last year, as Singapore...
Update: Oracle Fiscal Q4 Non-GAAP Earnings Fall, Sales Rise; Unveils Microsoft, Google Partnerships; Shares Gain Premarket
Update: Oracle Fiscal Q4 Non-GAAP Earnings Fall, Sales Rise; Unveils Microsoft, Google Partnerships; Shares Gain Premarket
Jun 12, 2024
04:57 AM EDT, 06/12/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Oracle (ORCL) shares were up 9% in premarket activity Wednesday after the company reported overnight an increase in fiscal Q4 sales and unveiled partnerships with Microsoft ( MSFT ) and Alphabet's (GOOG, GOOGL) Google ( GOOG ). The company reported fiscal...
China ready to defend interests as EU tariffs on EVs loom
China ready to defend interests as EU tariffs on EVs loom
Jun 12, 2024
BEIJING (Reuters) - China will take all necessary measures to firmly safeguard its lawful rights and interests after a newspaper reported that the European Commission would impose tariffs of up to 25% on imported Chinese electric vehicles (EVs), its foreign ministry said on Wednesday. After an eight-month long investigation, the Commission, which oversees trade policy for the 27-nation European Union,...
Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan
Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan
Jun 12, 2024
04:54 AM EDT, 06/12/2024 (MT Newswires) -- Belite Bio ( BLTE ) said Wednesday its oral tablet tinlarebant for the treatment of Stargardt disease has secured Sakigake, or pioneer drug designation, by the Ministry of Health, Labor and Welfare in Japan. Sakigake designation is intended to accelerate the drug approval process in Japan for innovative drugs with prominent effectiveness targeting...
Copyright 2023-2026 - www.financetom.com All Rights Reserved